Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-
axonal injury. The advent of highly sensitive analytical platforms that enable reliable …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's
disease and are at very high risk of develo** early-onset dementia, which is now the …

Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …

Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease
(AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of …

Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as …

Background Alzheimer's disease and its complications are the leading cause of death in
adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with …

Alzheimer disease (AD) represents an oncoming epidemic that without an effective
treatment promises to exact extraordinary human and financial burdens. Studies of …

Abstract Alzheimer's disease (AD), being the number one in terms of dementia burden, is an
insidious age-related neurodegenerative disease and is presently considered a global …

Blood-biomarker-based tests are highly important for the early clinical diagnosis of
Alzheimer's disease (AD) and the treatment and care of AD patients, but the complex serum …